XML 25 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020     129,344,000          
Beginning balance at Dec. 31, 2020 $ 609,635 $ (378,138) $ 129 $ 1,030,577 $ (465,006) $ 1,530 $ (422,601) $ 86,868
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock (in shares)     (8,403,000)          
Repurchase of common stock (300,000)   $ (8) (299,992)        
Issuance of common stock in connection with follow-on offering, net of offering costs (in shares)     10,975,000          
Issuance of common stock in connection with follow-on offering, net of offering costs 1,091,466   $ 11 1,091,455        
Equity component related to conversions of 2023 convertible senior notes (236,921)     (236,921)        
Issuance of common stock upon conversion of 2023 convertible senior notes (in shares)     2,983,000          
Issuance of common stock upon conversion of 2023 convertible senior notes 235,521   $ 3 235,518        
Net proceeds from capped call related to conversions and extinguishments of 2023 notes and 2025 notes 67,770     67,770        
Issuance of common stock upon exercise of stock options and ESPP (in shares)     413,000          
Issuance of common stock upon exercise of stock options and ESPP 8,885     8,885        
Net issuance of common stock for settlement of RSUs (in shares)     1,640,000          
Net share settlement of equity awards (94,421)   $ 2 (94,423)        
Share-based compensation expense 111,442     111,442        
Other comprehensive loss (6,864)         (6,864)    
Net loss (1,458)           (1,458)  
Ending balance (in shares) at Dec. 31, 2021     136,952,000          
Ending balance at Dec. 31, 2021 1,106,917   $ 137 1,449,305   (5,334) (337,191)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock (in shares)     (12,709,000)          
Repurchase of common stock (323,528)   $ (13) (323,515)        
Issuance of common stock upon exercise of stock options and ESPP (in shares)     437,000          
Issuance of common stock upon exercise of stock options and ESPP 6,475     6,475        
Net issuance of common stock for settlement of RSUs (in shares)     1,794,000          
Net share settlement of equity awards (26,547)   $ 2 (26,549)        
Share-based compensation expense 138,788     138,788        
Other comprehensive loss (52,154)         (52,154)    
Net loss $ 266,638           266,638  
Ending balance (in shares) at Dec. 31, 2022 126,473,827   126,474,000          
Ending balance at Dec. 31, 2022 $ 1,116,589   $ 126 1,244,504   (57,488) (70,553)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock (in shares)     (26,506,000)          
Repurchase of common stock (337,709)   $ (26) (337,683)        
Net proceeds from capped call related to conversions and extinguishments of 2023 notes and 2025 notes 297     297        
Issuance of common stock upon exercise of stock options and ESPP (in shares)     512,000          
Issuance of common stock upon exercise of stock options and ESPP 4,163   $ 1 4,162        
Net issuance of common stock for settlement of RSUs (in shares)     2,344,000          
Net share settlement of equity awards (16,438)   $ 2 (16,440)        
Share-based compensation expense 136,787     136,787        
Other comprehensive loss 22,749         22,749    
Net loss $ 18,180           18,180  
Ending balance (in shares) at Dec. 31, 2023 102,823,700   102,824,000          
Ending balance at Dec. 31, 2023 $ 944,618   $ 103 $ 1,031,627   $ (34,739) $ (52,373)